Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance

Circulation Journal

Volumn 75, Issue 4, 2011, Pages 964-969

  Yun, Ji Eun ^a   Kim, Sang Yeun ^a,b   Kang, Hee Cheol ^c   Lee, Sun Ju ^a,b   Kimm, Heejin ^a   Jee, Sun Ha ^a  

^a Yonsei University   (South Korea)

^b Metabolic Syndrome Research Initiatives   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Alanine aminotransferase; Insulin resistance; Metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH STATUS; HIGH RISK POPULATION; HUMAN; INSULIN RESISTANCE; KOREA; MALE; METABOLIC SYNDROME X; RISK ASSESSMENT; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INSULIN RESISTANCE; KOREA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 79953672503     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0465     Document Type: Article

References (40)

1. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414-419.
2. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEPdefined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214.
3. Tong PC, Kong AP, So WY, Yang X, Ho CS, Ma RC, et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1206-1211.
4. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Metabolic syndrome as a risk factor for coronary heart disease and stroke: An 11-year prospective cohort in Taiwan community. Atherosclerosis 2007; 194: 214-221.
5. Higashiyama A, Okamura T, Ono Y, Watanabe M, Kokubo Y, Okayama A. Risk of smoking and metabolic syndrome for incidence of cardiovascular disease: Comparison of relative contribution in urban Japanese population: The Suita study. Circ J 2009; 73: 2258-2263.
6. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.
7. Hunt KJ, Williams K, Hazuda HP, Stern MP, Haffner SM. The metabolic syndrome and the impact of diabetes on coronary heart disease mortality in women and men: The San Antonio Heart Study. Ann Epidemiol 2007; 17: 870-877.
8. Protopsaltis I, Nikolopoulos G, Dimou E, Brestas P, Kokkoris S, Korantzopoulos P, et al. Metabolic syndrome and its components as predictors of all-cause mortality and coronary heart disease in type 2 diabetic patients. Atherosclerosis 2007; 195: 189-194.
9. Saito I, Iso H, Kokubo Y, Inoue M, Tsugane S. Metabolic syndrome and all-cause and cardiovascular disease mortality: Japan Public Health Center-based Prospective (JPHC) Study. Circ J 2009; 73: 878-884.
10. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
11. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998; 27: 1213-1219.
12. Kahn RA, Johnson G, Aach RD, Hines A, Ellis FR, Miller WV. The distribution of serum alanine aminotransferase levels in a blood donor population. Am J Epidemiol 1982; 115: 929-940.
13. Oh SY, Cho YK, Kang MS, Yoo TW, Park JH, Kim HJ, et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 2006; 55: 1604-1609.
14. Hanley AJ, Wagenknecht LE, Festa A, D'Agostino RB Jr, Haffner SM. Alanine aminotransferase and directly measured insulin sensi tivity in a multiethnic cohort: The Insulin Resistance Atherosclerosis Study. Diabetes Care 2007; 30: 1819-1827.
15. Bo S, Gambino R, Durazzo M, Guidi S, Tiozzo E, Ghione F, et al. Associations between gamma-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a populationbased cohort: A possible implication for oxidative stress. World J Gastroenterol 2005; 11: 7109-7117.
16. Westerbacka J, Cornér A, Tiikkainen M, Tamminen M, Vehkavaara S, Häkkinen AM, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: Implications for sex differences in markers of cardiovascular risk. Diabetologia 2004; 47: 1360-1369.
17. Jeong SK, Nam HS, Rhee JA, Shin JH, Kim JM, Cho KH. Metabolic syndrome and ALT: A community study in adult Koreans. Int J Obes Relat Metab Disord 2004; 28: 1033-1038.
18. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: The insulin resistance atherosclerosis study. Diabetes 2005; 54: 3140-3147.
19. Schindhelm RK, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ, et al. Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: The Hoorn Study. Diabet Med 2007; 24: 430-435.
20. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
21. Steering Committee of the Western Pacific Region of the World Health Organization, the International Association for the Study of Obesity, and the International Obesity Task Force. The Asia-Pacific Perspective: Redefining Obesity and its Treatment. Melbourne: Health Communications Australia Pty Ltd, 2000.
22. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middleaged Japanese men. Diabetes Care 2004; 27: 1427-1432.
23. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
24. Onat A, Hergenç G, Türkmen S, Yazici M, Sari I, Can G. Discordance between insulin resistance and metabolic syndrome: Features and associated cardiovascular risk in adults with normal glucose regulation. Metabolism 2006; 55: 445-452.
25. Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am 2007; 91: 1063-1077.
26. Tzou WS, Douglas PS, Srinivasan SR, Bond MG, Tang R, Chen W, et al. Increased subclinical atherosclerosis in young adults with metabolic syndrome: The Bogalusa Heart Study. J Am Coll Cardiol 2005; 46: 457-463.
27. McNeil AM, Rosamond WD, Girman CJ, Heiss G, Golden SH, Duncan BB, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (the ARIC study). Am J Cardiol 2004; 94: 1249-1254.
28. Ellison RC, Shang Y, Wagenknecht LE, Eckfeldt JH, Hopkins PN, Pankow JS, et al. Relation of the metabolic syndrome to calcified atherosclerotic plaque in the coronary arteries and aorta. Am J Cardiol 2005; 95: 1180-1186.
29. Bertoni AG, Wong ND, Shea S, Ma S, Liu K, Preethi S, et al. Insulin resistance, metabolic syndrome, and subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2007; 30: 2951-2956.
30. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
31. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care 2000; 23: 57-63.
32. González-Ortiz M, Martínez-Abundis E. Comparison of several formulas to assess insulin action in the fasting state with the hyperglycemic-hyperinsulinemic clamp technique in healthy individuals. Rev Invest Clin 2003; 55: 419-422.
33. Kuzuya M, Ando F, Iguchi A, Shimokata H. Age-specific change of prevalence of metabolic syndrome: Longitudinal observation of large Japanese cohort. Atherosclerosis 2007; 191: 305-312.
34. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
35. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005; 365: 1398-1405.
36. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diab Res Clin Pract 2003; 61: 29-37.
37. Park HS, Lee SY, Kim SM, Han JH, Kim DJ. Prevalence of the metabolic syndrome among Korean adults according to the criteria of the International Diabetes Federation. Diabetes Care 2006; 29: 933-934.
38. Park HS, Kim SM, Lee JS, Lee J, Han JH, Yoon DK, et al. Prevalence and cardiovascular disease risk of the metabolic syndrome using National Cholesterol Education Program and International Diabetes Federation definitions in the Korean population. Metabolism 2007; 56: 552-558.
39. Cnop M, Landchild MJ, Vidal J, Havel PJ, Knowles NG, Carr DR, et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: Distinct metabolic effects of two fat compartments. Diabetes 2002; 51: 1005-1015.
40. Shimabukuro M. Cardiac adiposity and global cardiometabolic risk: New concept and clinical implication. Circ J 2009; 73: 27-34.